These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

154 related items for PubMed ID: 22825324

  • 21. Changes in total IgE plasma concentration measured at the third month during anti-IgE treatment predict future exacerbation rates in difficult-to-treat atopic asthma: a pilot study.
    Dal Negro RW, Guerriero M, Micheletto C, Tognella S, Visconti M.
    J Asthma; 2011 Jun; 48(5):437-41. PubMed ID: 21599560
    [Abstract] [Full Text] [Related]

  • 22. Diagnostic criteria of eosinophilic otitis media, a newly recognized middle ear disease.
    Iino Y, Tomioka-Matsutani S, Matsubara A, Nakagawa T, Nonaka M.
    Auris Nasus Larynx; 2011 Aug; 38(4):456-61. PubMed ID: 21251776
    [Abstract] [Full Text] [Related]

  • 23. Treatment of eosinophilic otitis media with pegylated interferon-α 2a and 2b.
    Neff BA, Voss SG, Carlson ML, O'Brien EK, Butterfield JH.
    Laryngoscope; 2017 May; 127(5):1208-1216. PubMed ID: 27667784
    [Abstract] [Full Text] [Related]

  • 24. Omalizumab protects against allergen- induced bronchoconstriction in allergic (immunoglobulin E-mediated) asthma.
    Zielen S, Lieb A, De La Motte S, Wagner F, de Monchy J, Fuhr R, Munzu C, Koehne-Voss S, Rivière GJ, Kaiser G, Erpenbeck VJ.
    Int Arch Allergy Immunol; 2013 May; 160(1):102-10. PubMed ID: 22948442
    [Abstract] [Full Text] [Related]

  • 25. Eustachian tube function in patients with eosinophilic otitis media associated with bronchial asthma evaluated by sonotubometry.
    Iino Y, Kakizaki K, Saruya S, Katano H, Komiya T, Kodera K, Ohta K.
    Arch Otolaryngol Head Neck Surg; 2006 Oct; 132(10):1109-14. PubMed ID: 17043260
    [Abstract] [Full Text] [Related]

  • 26. Monitoring free serum IgE in severe asthma patients treated with omalizumab.
    Korn S, Haasler I, Fliedner F, Becher G, Strohner P, Staatz A, Taube C, Buhl R.
    Respir Med; 2012 Nov; 106(11):1494-500. PubMed ID: 22884459
    [Abstract] [Full Text] [Related]

  • 27. Anti-immunoglobulin E treatment with omalizumab in allergic diseases: an update on anti-inflammatory activity and clinical efficacy.
    Holgate ST, Djukanović R, Casale T, Bousquet J.
    Clin Exp Allergy; 2005 Apr; 35(4):408-16. PubMed ID: 15836747
    [Abstract] [Full Text] [Related]

  • 28.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 29. Effects of omalizumab, a humanized monoclonal anti-IgE antibody, on nasal reactivity to allergen and local IgE synthesis.
    Corren J, Diaz-Sanchez D, Saxon A, Deniz Y, Reimann J, Sinclair D, Davancaze T, Adelman D.
    Ann Allergy Asthma Immunol; 2004 Sep; 93(3):243-8. PubMed ID: 15478383
    [Abstract] [Full Text] [Related]

  • 30. Myringoplasty for Eosinophilic Otitis Media.
    Kikuchi S, Yoshida S, Sugiyama T, Iino Y.
    Otol Neurotol; 2023 Jul 01; 44(6):572-577. PubMed ID: 37231536
    [Abstract] [Full Text] [Related]

  • 31.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 32.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 33. Anti-immunoglobulin E in the treatment of refractory atopic dermatitis.
    Kim DH, Park KY, Kim BJ, Kim MN, Mun SK.
    Clin Exp Dermatol; 2013 Jul 01; 38(5):496-500. PubMed ID: 23083013
    [Abstract] [Full Text] [Related]

  • 34. Risk factors for bacterial infection to cause sensorineural hearing loss in eosinophilic otitis media.
    Masuda M, Esu Y, Iino Y, Yoshida N.
    Auris Nasus Larynx; 2021 Apr 01; 48(2):207-213. PubMed ID: 32883575
    [Abstract] [Full Text] [Related]

  • 35.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 36. Omalizumab is effective in allergic and nonallergic patients with nasal polyps and asthma.
    Gevaert P, Calus L, Van Zele T, Blomme K, De Ruyck N, Bauters W, Hellings P, Brusselle G, De Bacquer D, van Cauwenberge P, Bachert C.
    J Allergy Clin Immunol; 2013 Jan 01; 131(1):110-6.e1. PubMed ID: 23021878
    [Abstract] [Full Text] [Related]

  • 37. Effectiveness of omalizumab in a patient with severe asthma, low serum IgE level, and lack of sensitized allergens induced by oral steroid therapy: the usefulness of impulse oscillation for assessment of omalizumab therapy.
    Matsuno O, Komori C, Hang Y, Matsumoto T, Minamoto S.
    J Asthma; 2012 Oct 01; 49(8):839-42. PubMed ID: 22920591
    [Abstract] [Full Text] [Related]

  • 38. Complete Remission of Severe Eosinophilic Otitis Media With Dupilumab: A Case Report.
    van der Lans RJL, van Spronsen E, Fokkens WJ, Reitsma S.
    Laryngoscope; 2021 Dec 01; 131(12):2649-2651. PubMed ID: 34216146
    [Abstract] [Full Text] [Related]

  • 39. Changes of immunomodulatory cytokines associated with omalizumab therapy for severe persistent asthma.
    Shimizu Y, Dobashi K, Fueki N, Fueki M, Okada T, Tomioka S, Makino S, Mori M.
    J Biol Regul Homeost Agents; 2011 Dec 01; 25(2):177-86. PubMed ID: 21880206
    [Abstract] [Full Text] [Related]

  • 40. [Eosinophilic otitis media].
    de Jong MA, Smithuis LO, Stokroos RJ.
    Ned Tijdschr Geneeskd; 2014 Dec 01; 158():A8044. PubMed ID: 25387983
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 8.